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Summary
Mutations in cerebral cavernous malformation 3 gene are known
to result in development of vascular malformations and have
recently been proposed to also give rise to meningiomas. We
report in this study that lack of CCM3 unexpectedly impairs the
senescence response of cells, and this is related to the inability of
CCM3-deficient cells to induce the C/EBPb transcription factor and
implement the senescence-associated secretory phenotype.
Induction of C/EBPb and cytokines is also impaired in the absence
of CCM3 in response to cytokines in nonsenescent cells, pointing
to it being a primary defect and not secondary to impaired
senescence. CCM3-deficient cells also have a defect in autophagy
at late passages of culture, and this defect is also not dependent
on impaired senescence, as it is evident in immortal cells after
nutrient starvation. Further, these two defects may be related, as
enforcing autophagy in CCM3-deficient late passage cells
increases C/EBPb cytokine expression. These results broaden our
knowledge on the mechanisms by which CCM3 deficiency results
in disease and open new avenues of research into both CCM3 and
senescence biology.
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Introduction
Cellular senescence develops in response to a variety of stresses,
including telomere attrition, unscheduled DNA replication, oxidative
stress, suboptimal culture conditions, or the presence of an activated
oncogene (in the latter case being called oncogene-induced senescence,
OIS) (Hayflick, 1965; Kuilman et al., 2010). It was first described in cells
in culture and is now widely accepted as an important antioncogenic
mechanism in vivo (Braig et al., 2005; Collado et al., 2005; Michaloglou
et al., 2005).
Some of the best known characteristics of senescent cells are those
that are directly related to their growth arrest, such as the activation of
p53 or the upregulation of the cyclin-dependent kinase inhibitors
p16ink4a or p21CIP1 (Campisi & d’Adda di Fagagna, 2007). However, in
the last few years, several other physiological changes have been shown
to be important for the full implementation of the senescence program;
among these are the secretion of a plethora of extracellular messengers,
most prominently cytokines, by senescent cells (Krtolica et al., 2001;
Coppe et al., 2006; Acosta et al., 2008; Kuilman et al., 2008; Kuilman &
Peeper, 2009), and the stimulation of the process of macroautophagy
(usually called simply autophagy) (Kurz et al., 2000; Young et al., 2009;
Narita et al., 2011). Autophagy is necessary in this context for the
efficient synthesis and secretion of extracellular messengers (Young
et al., 2009), and once established, the synthesis and secretion of
cytokines can be self-sustained by a positive feedback loop involving the
transcription factors NFjB and C/EBPb (Acosta et al., 2008).
Mutations in the CCM3/PDCD10 gene (CCM3 from here on)
predispose to cerebral cavernous malformations (CCM, OMIM
#116860), a common type of vascular malformation which develop
almost exclusively in the central nervous system (Rigamonti et al., 1988).
Its product is an adaptor protein that binds to the germinal center kinase
III (GCKIII) family of protein kinases (composed of Mst3/STK24, Mst4/
MASK, and SOK1/YSK1/STK25) through its N-terminal domain (Ma
et al., 2007; Voss et al., 2009; Fidalgo et al., 2010; Zalvide et al., 2013),
and to other proteins through its C-terminal end (Voss et al., 2007;
Goudreault et al., 2008; Fidalgo et al., 2010; Li et al., 2011). Several
functions have been proposed for CCM3, including modulation of cell
death, especially after oxidative stress (Chen et al., 2009; Schleider
et al., 2010; Fidalgo et al., 2012; Zhang et al., 2012), regulation of
transmembrane signaling and cell growth (Ma et al., 2007; Kleaveland
et al., 2009; He et al., 2010; Lin et al., 2010), and playing a role in
membrane trafficking, Golgi apparatus biogenesis, cell migration, and
regulated secretion (Fidalgo et al., 2010; Zhang et al., 2013; Louvi et al.,
2014).
Recently, patients carrying heterozygous CCM3 gene mutations have
been shown to be at high risk of developing meningiomas in which the
wild-type allele of CCM3 is mutated (Labauge et al., 2009; Riant et al.,
2013), which hints to a possible role of CCM3 as a tumor suppressor,
although no mechanism for such an effect has been proposed.
Here, we show that cells deficient in CCM3 do not enter senescence
after replicative stress or oncogene induction. Lack of CCM3 results in
impaired expression of cytokines and their regulator C/EBPb, both in
senescence and in response to cytokines. Moreover, CCM3-deficient
cells do not increase autophagy at late passages of culture or after
nutrient starvation.
Results
To study the biology of the cavernous malformation susceptibility gene
CCM3, we depleted the CCM3 protein in primary endothelial cells by
lentiviral transduction of CCM3 small hairpin RNAs. Two of the shRNAs –
shCCM3#1 and shCCM3#2 – we used gave a good downregulation of
CCM3 (Fig. 1A). As expected for primary cells, those infected with a
control shRNA stopped their proliferation when they reached between 6
and 12 population doublings, and showed the typical morphology of
senescent cells. Surprisingly, cells with a downregulated CCM3 contin-
ued to divide when they reached the same number of doublings. Cells
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infected with shCCM3#1 did not show a clear slowing in their
proliferation rate even after 25 population doublings, whereas cells
infected with the less effective shCCM3#2 shRNA had an intermediate
phenotype, proliferating longer than the control cells but ultimately
ceasing their division (Fig. 1B). Significantly, the proliferation during the
first divisions of the cells was undistinguishable in cells with different
levels of CCM3 (duplication time of 52.4  11.9 h for control vs.
56.7  14.2 h for CCM3 knockdown cells, P = 0.47), and their cell
cycle profile was also similar (Fig. S1A, Supporting information), which
pointed to a specific senescent defect. In the same analysis, no difference
in sub-2n DNA was found, suggesting also that lack of CCM3 does not
induce apoptosis at least in unstressed endothelial cells.
Consistently with an involvement in senescence, CCM3-depleted cells
did not acquire the morphology characteristic of senescent cells even
after 25 population doublings, and they did not accumulate senescence-
associated b-galactosidase (Fig. 1C). CCM3-depleted cells were clono-
genic, but did not form foci when allowed to grow to confluence (Fig.
S1B,C, Supporting information), and did not accumulate the cdk
inhibitors p21cip1 or p16ink4a (Fig. S1D,E, Supporting information). They
did show signs of low-intensity DNA damage, as seen by cH2AX levels
(Fig. S1F, Supporting information), and higher p53 levels than low
passage cells, although p53 could still respond to the intense DNA
damage induced by doxorubicin (Fig. S1G, Supporting information). To
further establish whether the effects of the shRNAs were due to CCM3
depletion and not to nonspecific effects of the shRNAs, we reexpressed
CCM3 with retroviral transduction. The shCCM3 #1 shRNA targets the
30 UTR of the CCM3 mRNA, and therefore, it does not have any effect
on a construct with the coding region of CCM3. CCM3 transduction
could recover CCM3 protein levels partially, and this was enough to
increase significantly the number of positive cells for SA-bGal activity
(Fig. 1D), indicating that senescence was being rescued.
To know how widespread the relation of CCM3 to senescence was,
we depleted this gene from IMR90 fibroblasts using a CCM3 shRNA
unrelated to those previously used (Fig. S2A, Supporting information).
CCM3-depleted fibroblasts did not enter senescence at the same
passage as control cells (Fig. S2B, Supporting information), although
they showed signs of senescence three passages later (not shown),
suggesting CCM3 only delays senescence in this model.
We hypothesized that if CCM3 was specifically required for replicative
senescence, its expression might be increased during the process.
However, CCM3 mRNA levels did not vary significantly as IMR90 cells
accumulated population doublings (Fig. S2C, Supporting information),
suggesting that if CCM3 is activated, it is through a mechanism different
than mRNA expression.
We then studied the effect of CCM3 in senescence in a well-known
model of senescence induction: IMR90 cells transduced with an onco-
genic H-ras switchable with the estrogen analog 4-hydroxytamoxifen (4-
OHT). When CCM3was inhibited in these cells (Fig. 2A), 4-OHT could still
increase the number of cH2AX-positive cells (Fig. 2B), showing that H-ras
was active in both control and CCM3-deficient cells. However, it did not
inhibit DNA synthesis (Fig. 2C), nor did it induce a senescent morphology
or senescence-associated b-galactosidase activity (Fig. 2D). Moreover,
depletion of CCM3 with completely unrelated shRNAs transduced by
retroviral vectors had the same effect (Fig. S2, Supporting information),
showing again that it is CCM3 downregulation and not a nonspecific




Fig. 1 CCM3-deficient endothelial cells do not undergo proliferative arrest. HCAEC cells were lentivirally infected with two different shRNA against CCM3 (shCCM3 #1 or
shCCM3 #2) or with a nontarget shRNA (shNT #1 or shNT #2). (A) CCM3 knockdown efficiency was assessed by Western blot. Tubulin is shown as a loading control.
(B) Cumulative population doublings in six independent populations of primary HCAEC cells transduced either with a nontarget shRNA (shNT), shCCM3#1, or shCCM3#2.
(C) Microphotographs showing SA-bGal activity in HCAEC shNT cells at population doublings 18, and shCCM3#1 cells cultures in parallel. Representative photographs
and a quantification of SA-bGal-positive cells (mean  SEM), n = 3. *P = 3.07 9 106. (D) Western blot of CCM3 showing the recovery of its levels after transduction
with pLOC or pLOC-CCM3 (upper panel); representative photographs of SA-bGal activity in HCAEC shNT and shCCM3#1 cells transduced with pLOC or pLOC-CCM3 (lower
panels); and quantification of SA-bGal-positive cells (mean  SEM), n = 3. *P = 2.4 9 106, #P = 0.018.
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Once we concluded that CCM3 depletion inhibited senescence in
several different models, we wanted to understand how CCM3 could
affect senescence in our original endothelial cells. Thus, we performed a
transcriptomic analysis comparing expression of genes regulated in
senescence in control cells (‘senescence genes’) between passage 12
shNT and shCCM3 cells (Fig. S4A, Supporting information). Gene set
enrichment analysis of this comparison against KEGG datasets showed
that two sets related to senescence were downregulated in shCCM3
cells: cytokine–cytokine receptor interaction and lysosome (Fig. S4B,
Supporting information). Indeed, expression of IL-6 and IL-8 mRNAs was
lower in late passage CCM3-depleted cells than in control cells as
assessed by quantitative RT–PCR (Fig. 3A). Also, while late passage
control cells secreted high quantities of IL-6, IL-8, and TGF-b2 to their
medium, cells without CCM3 did not (Fig. 3B). Interestingly, control cells
at high passage had a higher activity of caspase-1 than shCCM3 cells
(Fig. 3C), suggesting that the inflammasome is activated differently
depending on the CCM3 status, which might affect cytokine response to
inflammation-related stimuli.
Regulation of cytokines during senescence depends on a network of
positive feedback loops whereby some cytokines stimulate their own
expression or that of related molecules (Acosta et al., 2008; Kuilman
et al., 2008; Acosta et al., 2013). To assess the regulation of cytokine
expression by CCM3, we studied the response of cells to TNF, which is
known to regulate IL-8 and IL-6 in endothelial cells. TNF could induce
both IL-6 and IL-8 mRNA in a time-dependent manner in control cells,
and this response was clearly impaired in CCM3-deficient cells (Fig. 4A).
The same was true for IL-8 intracellular protein levels and extracellular
secretion (Fig. 4B,C). Furthermore, TNF could induce the nuclear
translocation of the transcriptional cytokine regulator NFjB and increase
the mRNA levels of the other principal regulator, C/EBPb. In the absence
of CCM3, the nuclear translocation of NFjB was unaffected while the
increase in C/EBPb mRNA was impaired (Fig. 4D,E). This defect in
cytokine regulation was not limited to the response to TNF. Treatment
with recombinant IL-8 induced the mRNAs of IL-6 and IL-8 in control but
not CCM3-deficient cells, and this was also accompanied by an impaired




Fig. 2 CCM3 depletion bypasses oncogene-induced senescence (OIS) in IMR90 cells. IMR90 cells expressing a switchable version of H-Ras (activated upon addition of 4-
hydroxytamoxifen, 4-OHT) were infected with a lentiviral CCM3 shRNAs (shCCM3) or nontarget shRNA (shNT), or with a retroviral p16 shRNA (shp16) or nontarget shRNA
(pRS), and then selected with puromycin. (A) CCM3 mRNA levels were assessed by qRT–PCR. n = 3, *P = 0.012 vs. shNT. (B) pH2AX-positive cells in the different
populations untreated or after 5 days of H-Ras activation (4-OHT). For B and C, the nuclear intensity average of the staining correlated to the shown percentage of positive
cells. (C) Percentage of BrdU-positive cells treated as in B, n = 3. *0.002, 0.005, 0.0002 vs. untreated control. (D) SA-bGal activity in the same cells under the same





Fig. 3 CCM3 knockdown endothelial cells show lower levels of SASP components
and inflammasome activation. (A) mRNA levels of IL-6 and IL-8 from shCCM3 and
shNT cells with 7 (PD7) or 12 (PD12) population doublings. n = 4, *P = 0.019,
0.023; and 0.017, and 0.04 vs. shNT. (B) Secretion of SASP components (IL-6, IL-8
and TGF-b2) in cell culture supernatants. n = 3, *P = 0.028, 0.048, 0.035, and
1.25 9 104 vs. shNT. (C) Activity of caspase-1 in late passage (PD18) shNT and
shCCM3 HCAEC cells. *P = 1.8 9 104.
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regulatory network of cytokine regulation was impaired in CCM3-
deficient cells, and this was closely related to their inability to induce the
C/EBPb transcriptional regulator.
C/EBPb was also induced in late passage (senescent) control cells but
not in CCM3-deficient cells (Fig. 5A). Moreover, when the expression of
C/EBPb was enforced in late passage shCCM3 HCAEC cells, a
significant percentage of them accumulated SA-bGal activity and
acquired a senescent-like morphology (Fig. 5B), suggesting that
CCM3 facilitates senescence at least in part through its effects on C/
EBPb expression.
Recently, the combination of autophagy and mTOR activity in a newly
defined cellular compartment called TOR-autophagy spatial coupling
compartment (TASCC), where lysosomes and mTOR accumulate, has
been proposed to be essential for cytokine secretion during senescence.
The lysosome gene set is also downregulated in late passage shCCM3
cells, and CCM3 has been implicated in Golgi biogenesis, vesicular
trafficking, and regulated secretion (Fidalgo et al., 2010; Kean et al.,
2011; Zhang et al., 2013). Thus, we hypothesized that formation of
TASCC might be altered in CCM3-deficient cells. As expected, senescent
control cells displayed a prominent protein degradation machinery as
seen by LAMP2 and p62 staining together with high levels of mTOR,
suggestive of the existence of the TASCC complex. On the contrary, cells
without CCM3 did not show any signs of TASCC (Fig. 6A).
TOR-autophagy spatial coupling compartment is formed by the
accumulation of mTOR and lysosomes that result from the high
autophagic activity of senescent cells (Narita et al., 2011). As CCM3 is
involved in vesicular traffic, we reasoned that it might have an effect on







Fig. 4 CCM3 is necessary for cytokine-
induced C/EBPb and cytokine induction. (A)
Induction of IL-6 and IL-8 mRNAs by TNF is
dependent on CCM3. Control (shNT) and
shCCM3 HCAEC cells were either treated
for 1 or 6 h with TNF 20 ng mL1, or left
untreated. Levels of IL-6 and IL-8 mRNAs
were determined. n = 3, *P = 0.028 and
0.003 vs. shNT cells. (B) IL-8 induction by
TNF depends on CCM3. HCAEC cells were
either treated with 2 ng mL1 or
20 ng mL1 TNF, or left untreated. IL-8
levels were determined by Western blot.
Tubulin is shown as a loading control. (C)
Stimulation of IL-8 secretion by TNF
depends on CCM3. Levels of IL-8 were
determined in cell culture supernatants by
ELISA, after treatment with 2 ng mL1 or
20 ng mL1 TNF. n = 3, *P = 5.0 9 103,
2.4 9 104, 7.3 9 103 vs. shNT. (D)
CCM3 status does not affect NFjB nuclear
translocation. Immunofluorescence
showing NFjB activation after TNF
20 ng mL1 treatment in control and
shCCM3 cells. The bar represents 20 lm.
(E) TNF induces C/EBPb mRNA in a CCM3-
dependent manner. HCAEC cells were
either treated for 1 or 6 h with TNF
20 ng mL1, or left untreated. Levels of C/
EBPb mRNA were determined. n = 3,
P = 0.035 vs. shNT cells. (F) Induction of
cytokines and C/EBPb by IL-8 is dependent
on CCM3. Control (shNT) and shCCM3
HCAEC cells were grown in the presence or
absence of 200 ng lL1 h1 IL-8, and
levels of IL-6, IL-8 and C/EBPb mRNAs were
determined. n = 4, *P = 0.004, 0.007,
0.0001, 0.001, 0.035, and 0.023 vs. shNT.
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cells by measuring the lipidated form of LC3B, LC3B-II, by Western blot,
and estimated autophagy flux as the difference in LC3B-II levels between
cells with and without treatment with bafilomycin A (BAF), which inhibits
autophagosome–lysosome fusion (Klionsky et al., 2012). As described,
autophagy is elevated in late passage control cells. However, late
passage cells with silenced CCM3 did not show the same induction of
autophagy (Fig. 6B).
Our results showed that CCM3-deficient cells had a defect in both
autophagy and C/EBPb induction in several circumstances. Both effects
were related. The expression of C/EBPb in late passage shCCM3 cells
induced an accumulation of LC3B-II (Fig. 6C). Further, enforced induc-
tion of autophagy transiently induced C/EBPb and cytokine mRNAs. As
seen in Fig. 6D, the mTOR inhibitor Torin1 could induce autophagy in
CCM3-deficient endothelial cells, as assessed by the accumulation of
LC3B-II after treatment with bafilomycin. When autophagy was induced,
there was an accumulation of IL-6, IL-8, and C/EBPb mRNAs in CCM3-
deficient cells (Fig. 6D, lower graph). This induction was visible only at
early times after Torin1 treatment and was reverted as soon as after
24 h, which we interpret to reflect the need of mTOR activity in the full
induction of senescence.
We reasoned that if autophagy impairment is a primary effect of lack of
CCM3, it should be evident independently of senescence. Thus, we
inhibited CCM3 in an immortal cell line derived from retinal epithelial cells
(hTERT-RPE1) (Fig. S5A, Supporting information) and then induced
autophagy by incubating them in Hank’s Buffered Saline Solution (HBSS),
a medium poor in amino acids. Lack of CCM3 did not apparently affect
autophagy flux of hTERT-RPE1 cells when grown in completemedium, but
inhibited its stimulation by nutrient starvation (Fig. S5B, Supporting
information). When we monitored autophagy by counting the LC3B-
positive punctae per cell, we also found that nutrient starvation induced
significantlymore punctaewhenCCM3was present (Fig. S5C, Supporting
information). CCM3 did not affect the number of punctae in cells in
complete medium significantly, although in this case there was a trend
toward there being less punctae in CCM3-deficient cells. Further,
impairment of autophagy is a consequence of CCM3 silencing, because
enforcedexpressionofCCM3protein results in recoveryof autophagic flux
after nutrient starvation (Fig. S5D, Supporting information).We concluded
from the above experiments that lack of CCM3 impaired the entry of cells
into senescence througheffects on autophagy,which resulted in inhibition
of C/EBPb induction, and of the senescence-associated secretome.
Discussion
We show here that CCM3 is important for senescence in primary cells
and propose that the link between CCM3 and senescence is its
involvement in autophagy and TASCC formation, which are essential for
the induction of the transcription factor C/EBPb and the production of
senescence-associated cytokines. These results shed new light in the
actions of CCM3 at the cellular level and into the relations between
autophagy, C/EBPb, and senescence.
CCM3 is involved in autophagy, not only during senescence but also
after nutrient deprivation in postsenescent cells. As CCM3 is important
for certain aspects of membrane handling in the cell, such as Golgi
biogenesis and regulated secretion, we expect it to be involved in the
early stages of autophagosome formation. In fact, the ability of CCM3 to
bind to phosphatidylinositols on one end and kinases of the GCKIII family
on the other (Sugden et al., 2013; Zalvide et al., 2013), and its action
modulating the binding of the STK24 kinase to the secretory regulator
UNC13D (Zhang et al., 2013), may be important for its autophagy
promoting function.
CCM3 is also important in the induction of the transcriptional
regulator C/EBPb, both during senescence and in response to cytokines,
two responses that may be related given the importance of cytokine–
cytokine networks in the senescence process. The experiments also
suggest that C/EBPb expression depends upon autophagy induction, at
least in some settings. Because C/EBPb can also stimulate autophagy, as
it has also been found in other systems (Ma et al., 2011; Guo et al.,
2013), we propose there is a positive feedback loop between this
transcription factor and autophagy during senescence. C/EBPb has been
proposed to contribute to the cell cycle arrest in senescence by inducing
the expression of cdk inhibitors such as p15ink4b in models where this is
the principal inhibitor induced (Kuilman et al., 2008). Also, the senes-
cence-associated secretion has been shown to induce many of the
features of senescence in a paracrine manner (Acosta et al., 2013). Thus,
we hypothesize that lack of C/EBPb expression underlies the lack of
induction of senescence markers in CCM3 silenced cells and their
inability to growth arrest. This is supported by the rescue of the
senescence phenotype by enforced expression of C/EBPb.
Our results add to our knowledge of cellular functions of CCM3,
which has been implicated in cell death and in regulation of cell
proliferation. CCM3 overexpression has been shown to induce apopto-
sis, and its inhibition to protect from necrosis after oxidative stress; and
from apoptosis after serum deprivation, cycloheximide treatment, or
(A)
(B)
Fig. 5 CCM3 is necessary for C/EBPb in senescence and C/EBPb overexpression
rescues senescence in CCM3-deficient cells. (A) Induction of C/EBPb in senescence
depends on CCM3. C/EBPb mRNA (graph) and protein (right panel) were
determined in control (shNT) and shCCM3 HCAEC cells of population doubling 7
(PD7) or 12 (PD12) by qRT–PCR or Western blot. n = 4, *P = 0.029 vs. shNT. (B)
Rescue of C/EBPb induces senescence in late passage shCCM3 HCAEC cells. Lower
panel, left: Western blot of C/EBPb in shNT and shCCM3 cells transduced with
pLOC or pLOC-C/EBPb at population doublings 18. Upper panels:
Microphotographs showing SA-bGal activity in HCAEC shNT cells at population
doublings 18, and shCCM3 HCAEC cells transduced with pLOC or pLOC-C/EBPb.
Lower panel, right: quantification of SA-bGal-positive cells (mean  SEM), n = 3.
*P = 2.4 9 106. #P = 0.033.
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depletion of c-protocadherins (Chen et al., 2009; Lin et al., 2010; Louvi
et al., 2011; Fidalgo et al., 2012). We have not challenged our cells with
death inducing factors so that we do not observe cell death which CCM3
might inhibit, either by sub-2n DNA or nuclear morphology. Thus, we
propose that the senescent effect of CCM3 is independent of its
apoptosis regulating functions. We also do not see an effect on
proliferation in early passage endothelial cells. This is consistent with the
results reported for HuVEC cells, in which a marginal effect or no effect
at all of CCM3 depletion on proliferation is seen (Schleider et al., 2010;
Zhu et al., 2010), and opposed to the clear effect of CCM3 inhibition on
proliferation in astrocytes (Louvi et al., 2011).
Patients with a heterozygous mutation of CCM3 have a high
susceptibility to develop cerebral cavernous malformations, and it has
been shown recently that they can also develop meningiomas, which
places CCM3 as a possible tumor suppressor gene (Clark et al., 2013;
Riant et al., 2013). Despite intensive research in the last years, the
mechanism by which lack of CCM3 (or lack of CCM1 or CCM2) in
endothelial cells results in cavernous malformations is still the subject of
debate. Defects in cellular death, polarization, migration, adhesion, and
also in endothelial barrier functions, angiogenesis, and differentiation
have all been proposed as contributing to cavernoma development (for a
review, see Fischer et al., 2013). Our results add a new defect of
endothelial cells lacking a CCM gene, the inability to enter senescence.
While endothelial cell senescence is usually related to aging, senescent
cells can develop prematurely as a consequence of cell stress, and new
evidence suggests that senescence may also be a developmentally
regulated process that contributes to the disposal of surplus cells
(Munoz-Espin et al., 2013; Storer et al., 2013). Experiments designed to
analyze whether senescent endothelial cells appear in the brain under
specific circumstances, such as angiogenesis, are needed to further study
the possible relation between senescence and the development of
cavernous malformations.
Mutations of the CCM3 gene can also result in multiple meningio-
mas, and the ability of CCM3 to induce senescence is likely to contribute
to their development. This opens a new avenue of research on the
relation between CCM3, senescence, and meningioma development.
(A)
(B) (C) (D)
Fig. 6 CCM3 is important for autophagy induction during senescence. (A) TOR-autophagy spatial coupling compartment (TASCC) markers in control (shNT) and shCCM3
HCAEC cells as seen by immunofluorescence. Upper photographs show the costaining of p62/SQSTM1 and mTOR. Medium photographs show the costaining of the
lysosomal marker LAMP2 and mTOR. Lower photographs show the staining of the trans-Golgi marker TGN46 and the lysosomal marker LAMP2. The bar represents 20 lm.
(B) Western blot for LC3B in shNT and shCCM3 HCAEC cells at population doubling 7 and 18. Where indicated, cells were treated with autophagy inhibitor bafilomycin
100 nM for 1 h. LC3B-II levels were determined by fluorescent Western blot. Tubulin is shown as a loading control. Right panel: autophagic flux under each condition. (C) C/
EBPb expression induces autophagy in late passage CCM3-deficient cells. Western blot of LC3B-II in HCAEC cells transduced with pLOC or pLOC-C/EBPb. (D) Induction of
autophagy by mTOR inhibition upregulates IL-6, IL-8, and C/EBPb levels in endothelial cells deficient for CCM3. Cells were treated with Torin1 for 4 h and incubated with
bafilomycin 1 for the last hour where indicated. Accumulation of LC3B-II was quantified by Western blot. Levels of IL-6, IL-8, and C/EBPb mRNAs were then determined by
qRT–PCR after treatment with Torin1 250 nM for the indicated hours. n = 3, *P = 0.043, 5 9 106, and 0.044 vs. untreated cells.
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Experimental procedures
Antibodies and plasmids
The antibodies used in this study were as follows: TGN46 (Abcam;
ab16052); CCM3 (Acris; AP26023PU-N); BrdU (BD Biosciences; 555627),
Lamp-2 (BD Biosciences; 555803), p21CIP1 (F-5) (Santa Cruz; sc-6246),
p16INK4 (BD Biosciences; 511325), p62 (BD Biosciences; 610832);
GAPDH (Calbiochem; CB-1001); LC3B (Cell Signaling; 3868), mTOR
(Cell Signaling; 2983); H2AX (Ser139) (Millipore; 05-636); IL-8 (500-P28)
(PeproTech; 500-P28); NFjB p65 (Santa Cruz; sc-8008); p53 (DO-1)
(Santa Cruz; sc-126); C/EBPb (Santa Cruz; sc-150); and tubulin (T5168)
(Sigma-Aldrich). The secondary antibodies used were as follows: goat
anti-rabbit DyLightTM 800, goat anti-mouse DyLightTM 680 (Thermo
Scientific); goat anti-mouse Alexa 488, goat anti-rabbit Alexa 488, goat
anti-mouse Alexa 594, and goat anti-rabbit Alexa 546 (Molecular
Probes).
All plasmids were constructed using standard molecular biology
techniques.
Cell culture
HCAEC cells, hTERT-RPE1, and IMR90 cells were obtained from
European Collection of Cell Cultures and were grown as recommended.
Replicative senescence was induced in HCAEC cells by passaging them
every 2 days in MesoEndo Cell Growth Medium 212-500 (Cell
Applications, Inc.). Oncogene-induced senescence was induced in ER:
Ras-IMR90 by treatment with hydroxytamoxifen for 5 days. All exper-
iments where population doublings are specified refer to shCCM3 cells
of those population doublings or shNT cells cultured in parallel for the
same time.
shRNA-mediated knockdown and recovery
Stable cell populations with silenced CCM3 or control were obtained via
selection after lentiviral transduction using MISSION lentiviral nontarget
shRNA control transduction particles or MISSION lentiviral shRNA
transduction particles against human CCM3, from Sigma-Aldrich
(TRC), or by retroviral transduction where stated. shRNAs sequences
are available upon request. Lentiviral transduction of CCM3 and C/EBPb
was performed using plasmids from the Precision LentiORF Collection
(Thermo Scientific Open Biosystems). Transduced cells were then
selected by blasticidin.
Treatments
HCAEC cells were treated with doxorubicin (Sigma-Aldrich) 1 lM for
24 h. hTERT-RPE1 cells were treated HBSS (Invitrogen) for 4 h to trigger
autophagy. In the last hour, cells were treated with bafilomycin A1
(Calbiochem) 0.1 lM, or left untreated. HCAEC cells were grown in the
presence of recombinant human IL-8 or TNF (R & D Systems)
200 ng lL1. mTOR activity was inhibited with Torin1 (Tocris) 250 nM.
IMR90 cells were treated with 4-hydroxytamoxifen (Sigma-Aldrich)
200 nM to activate Ras in IMR90 Ras:ER.
Immunofluorescence and image analysis
HCAEC and hTERT-RPE1 cells were fixed, permeabilized, blocked, and
incubated with primary antibodies overnight at 4 °C in PBS + 1% BSA.
DNA was stained with Hoechst 33342. Confocal images were collected
using a Leica confocal microscope equipped with an HCX PL APO CS
63x/1.32 objective. Leica LCS software was used for acquisition and
analysis. Images are combinations of optical sections taken in the z-axis
at 0.13-lm intervals. Immunofluorescences in IMR90 cells were analyzed
using the high-throughput InCell Analyzer 1000 (GE Healthcare)
following manufacturer’s instructions.
Western blot analysis
Western blotting was performed by standard procedures. Signals were
quantified with LI-COR Odyssey software.
Senescence-associated b-galactosidase assay
Cells were fixed and stained for SA-bGal by standard protocols.
Quantification was performed by two independent observers.
Quantitative RT–PCR
Primers for TaqMan analysis were from Roche Diagnostics: Samples were
normalized to ACTB and RPLP0. Primers for TaqMan analysis were from
Roche Diagnostics: ACTB (101125), C/EBPb (100269), IL-6 (113614), IL-8
(103136), LC3B (144005), and RPLP0 (101144).
ELISAs and conditioned media
ELISA kits to detect IL-6, IL-8, and TGF-b2 were from Gen-Probe
Diaclone. CM was prepared by washing with serum-free DMEM and
incubating in serum-free DMEM for 24 h. All ELISA data were
normalized to cell number.
Caspase-1 activity
Caspase-1 activity was measured with a caspase-1 fluorometric assay kit
(R & D systems) following manufacturer’s instructions.
Flow cytometry
Cell cycle distribution experiments were performed using a FACScan
flow cytometer (Becton & Dickinson, San Jose, CA, USA) and analyzed
using FLOWJO software.
Microarrays
RNA extracts from HCAEC cells were obtained using Trizol reagent (Life
Technologies) and quantified with a NanoDrop 2000 (Thermo Scientific).
RNA quality was assessed using a RNA 6000 Nano Kit (Agilent
Biotechnologies). Microarrays were prepared using the following kits:
Ambion WT Expression Kit (Life Technologies) and Human GeneChip
Whole Transcript Terminal Labeling Expression Kit (Affymetrix). RNAs
were hybridized to GeneChip Human Gene 1.0 ST Arrays. Genes
differentially expressed between shNT p7 and p12 cells (senescence
genes) were ranked according to their relative expression between
shCCM3 and shNT p12 cells and used for gene set enrichment analysis
(Subramanian et al., 2005) against gene sets from KEGG pathways. The
microarray data from this publication have been submitted to the Gene
Expression Omnibus Data Repository and assigned the identifier
GSE54095.
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Statistical analysis
The statistical significance of all data obtained was assessed by Student’s
t-tests, or ANOVA testing followed by Bonferroni correction where
several comparisons were made, using SPSS software version 12.0.0. All
experiments where statistical significance is shown were repeated a
minimum of three times.
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Fig. S5 CCM3 role in autophagy is independent of senescence.
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